Research outputs
2026
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During Coronavirus Disease 2019: Lessons Learned for Future Pandemic Preparedness
Kuriakose, S., Tseng, A., Boyd, S., Gibbons, S., Chiong, J., Marra, F., . . . Marzolini, C. (2026). International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During Coronavirus Disease 2019: Lessons Learned for Future Pandemic Preparedness. CLINICAL INFECTIOUS DISEASES, 82(3), e446-e454. doi:10.1093/cid/ciaf606
Polypharmacy in HIV: Rethinking what counts and why it matters
Sukumaran, L., Winston, A., Marzolini, C., Khoo, S., Boffito, M., Naous, N., & Sabin, C. A. (2026). Polypharmacy in HIV: Rethinking what counts and why it matters. HIV Medicine, 27(2), 186-199. doi:10.1111/hiv.70129
2025
Leukocyte count and new-onset diabetes mellitus in people with HIV: A longitudinal study.
Meyer, S. C., Klein, Z., Schoepf, I. C., Thorball, C. W., Labarile, M., Kootstra, N. A., . . . Swiss HIV Cohort Study. (2025). Leukocyte count and new-onset diabetes mellitus in people with HIV: A longitudinal study.. HIV medicine, 26(10), 1585-1599. doi:10.1111/hiv.70089
Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?
Thoueille, P., Marzolini, C., Guidi, M., Cavassini, M., & Decosterd, L. A. (2025). Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 81(1), e4-e5. doi:10.1093/cid/ciae616
Types of Myocardial Infarction in People With HIV in Switzerland.
Kleynhans, J. N., Cobo, N. N., Avery, E. F., Buechel, R. R., Thorball, C. W., Schoepf, I. C., . . . Swiss HIV Cohort Study . (2025). Types of Myocardial Infarction in People With HIV in Switzerland.. Open forum infectious diseases, 12(7), ofaf357. doi:10.1093/ofid/ofaf357
A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring
D’Atri, V., Corrado, F., Versace, F., Saldanha, S. A., Mercier, T., Guidi, M., . . . Choong, E. (2025). A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules, 30(9). doi:10.3390/molecules30091866
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine
Pallanza, M., Thoueille, P., Briki, M., Alves Saldanha, S., Cavassini, M., & Marzolini, C. (2025). Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine. Antiviral Therapy, 30(2). doi:10.1177/13596535251335080
Individualization of piperacillin dosage based on therapeutic drug monitoring with or without model-informed precision dosing: a scenario analysis
Haefliger, D., Mina, L., Guidi, M., Marzolini, C., Thoueille, P., Rothuizen, L. E., . . . Buclin, T. (2025). Individualization of piperacillin dosage based on therapeutic drug monitoring with or without model-informed precision dosing: a scenario analysis. Journal of Antimicrobial Chemotherapy, 80(3), 840-847. doi:10.1093/jac/dkaf007
2024
Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir.
Marzolini, C., Gibbons, S., Seddon, D., & Khoo, S. (2024). Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir.. Expert opinion on drug metabolism & toxicology, 1-12. doi:10.1080/17425255.2024.2415295
Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV
Damas, J., Munting, A., Fellay, J., Haerry, D., Marzolini, C., Tarr, P. E., . . . Yerly, S. (2024). Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV. Clinical Infectious Diseases, 79(4), 990-998. doi:10.1093/cid/ciae189
Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure
Berton, M., Stader, F., Bettonte, S., Battegay, M., & Marzolini, C. (2024). Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure. Open Forum Infectious Diseases, 11(10). doi:10.1093/ofid/ofae585
Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk
Abela, I. A., Chammartin, F., Amstutz, A., Surial, B., Ballif, M., Marzolini, C., . . . Pasin, C. (2024). Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk. Open Forum Infectious Diseases, 11(9). doi:10.1093/ofid/ofae502
Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report
Haefliger, D., Chehade, H., Livio, F., Rodrigues-Veiga, V., Diezi, L., & Marzolini, C. (2024). Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report. Seminars in Dialysis, 37(6), 461-465. doi:10.1111/sdi.13224
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2024). Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study. Clinical Infectious Diseases, 79(2), 477-486. doi:10.1093/cid/ciae060
Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations
Bongiovanni, M., Thoueille, P., Barda, B., Mercier, T., Marzolini, C., Ramponi, N., . . . Bernasconi, E. (2024). Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations. European Journal of Clinical Microbiology and Infectious Diseases, 43(7), 1503-1504. doi:10.1007/s10096-024-04844-5
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV
Thoueille, P., Saldanha, S. A., Schaller, F., Choong, E., Veuve, F., Munting, A., . . . Guidi, M. (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. Clinical Pharmacology and Therapeutics, 115(6), 1450-1459. doi:10.1002/cpt.3240
DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy.
Pham, T., Ghafoor, M., Grañana-Castillo, S., Marzolini, C., Gibbons, S., Khoo, S., . . . Siccardi, M. (2024). DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy.. NPJ systems biology and applications, 10(1), 48. doi:10.1038/s41540-024-00374-0
Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs
Bettonte, S., Berton, M., Battegay, M., Stader, F., & Marzolini, C. (2024). Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs. Cpt Pharmacometrics and Systems Pharmacology, 13(5), 781-794. doi:10.1002/psp4.13118
Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2024). Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study. Open Forum Infectious Diseases, 11(4). doi:10.1093/ofid/ofae171
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update
Briki, M., Murisier, A., Guidi, M., Seydoux, C., Buclin, T., Marzolini, C., . . . Decosterd, L. A. (2024). Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 1236. doi:10.1016/j.jchromb.2024.124039
Population pharmacokinetic analysis of doravirine in real-world people with HIV
Thoueille, P., Delarive, L., Cavassini, M., Buclin, T., Decosterd, L. A., Marzolini, C., . . . Guidi, M. (2024). Population pharmacokinetic analysis of doravirine in real-world people with HIV. British Journal of Clinical Pharmacology, 90(4), 1058-1065. doi:10.1111/bcp.15975
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study
Ambrosioni, J., Diaz, N. A., Marzolini, C., Dragovic, G., Imaz, A., Calcagno, A., . . . Molto, J. (2024). Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study. INFECTIOUS DISEASES AND THERAPY, 13(3), 609-617. doi:10.1007/s40121-024-00935-0
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures
Thoueille, P., Cavassini, M., Guidi, M., Buclin, T., Girardin, F. R., Decosterd, L. A., & Marzolini, C. (2024). Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures. Open Forum Infectious Diseases, 11(2). doi:10.1093/ofid/ofae023
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data
Berton, M., Bettonte, S., Stader, F., Decosterd, L., Tarr, P. E., Livio, F., . . . Marzolini, C. (2024). Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data. Clinical Infectious Diseases, 78(1), 98-110. doi:10.1093/cid/ciad495
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
Thoueille, P., Saldanha, S. A., Schaller, F., Choong, E., Munting, A., Cavassini, M., . . . Decosterd, L. A. (2024). Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. Lancet Regional Health Europe, 36. doi:10.1016/j.lanepe.2023.100793
2023
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2023). Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen. British Journal of Clinical Pharmacology, 89(12), 3618-3628. doi:10.1111/bcp.15867
Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient
Erba, A., Marzolini, C., Rentsch, K., Stoeckle, M., Battegay, M., Mayr, M., & Weisser, M. (2023). Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient. Virology Journal, 20(1). doi:10.1186/s12985-023-02058-3
Letter to the Editor: People living with HIV and NAFLD—A population left behind in the global effort for liver fibrosis screening?
Sebastiani, G., Milic, J., Tsochatzis, E. A., Marzolini, C., Betel, M., Bhagani, S., . . . Guaraldi, G. (2023). Letter to the Editor: People living with HIV and NAFLD—A population left behind in the global effort for liver fibrosis screening?. Hepatology, 78(5), E87-E88. doi:10.1097/HEP.0000000000000465
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023
Ambrosioni, J., Levi, L., Alagaratnam, J., Van Bremen, K., Mastrangelo, A., Waalewijn, H., . . . Rockstroh, J. K. (2023). Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Medicine, 24(11), 1126-1136. doi:10.1111/hiv.13542
Population Pharmacokinetic Analysis of Doravirine in Real-World People with HIV
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study
Schwenke, J. M., Thorball, C. W., Schoepf, I. C., Ryom, L., Hasse, B., Lamy, O., . . . Yerly, S. (2023). Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study. Journal of Infectious Diseases, 228(6), 742-750. doi:10.1093/infdis/jiad179
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen
Marzolini, C., Cavassini, M., Braun, D. L., Hachfeld, A., Bernasconi, E., Calmy, A., . . . Elzi, L. (2023). Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen. British Journal of Clinical Pharmacology, 89(9), 2739-2746. doi:10.1111/bcp.15754
Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole
Haefliger, D., Marzolini, C., Lamoth, F., Pabst, T., Buclin, T., & Livio, F. (2023). Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole. British Journal of Clinical Pharmacology, 89(7), 2304-2308. doi:10.1111/bcp.15743
Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
Berton, M., Bettonte, S., Stader, F., Battegay, M., & Marzolini, C. (2023). Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers. Open Forum Infectious Diseases, 10(7). doi:10.1093/ofid/ofad361
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2023). Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. European Journal of Drug Metabolism and Pharmacokinetics, 48(4), 353-362. doi:10.1007/s13318-023-00833-9
Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years
Schoepf, I. C., Esteban-Cantos, A., Thorball, C. W., Rodés, B., Reiss, P., Rodríguez-Centeno, J., . . . Tarr, P. E. (2023). Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years. Lancet Healthy Longevity, 4(5), e211-e218. doi:10.1016/S2666-7568(23)00037-5
Management of Drug-Drug Interactions between Long-Acting Cabotegravir and Rilpivirine and Comedications with Inducing Properties: A Modeling Study
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2023). Management of Drug-Drug Interactions between Long-Acting Cabotegravir and Rilpivirine and Comedications with Inducing Properties: A Modeling Study. Clinical Infectious Diseases, 76(7), 1225-1236. doi:10.1093/cid/ciac901
Response to "A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir"
Marzolini, C., & Khoo, S. (2023). Response to "A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir". CLINICAL PHARMACOLOGY & THERAPEUTICS, 113(4), 770. doi:10.1002/cpt.2809
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
Berton, M., Bettonte, S., Stader, F., Battegay, M., & Marzolini, C. (2023). Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals. Clinical Pharmacokinetics, 62(2), 277-295. doi:10.1007/s40262-022-01194-3
Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature
Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Granana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 92(2), 97-105. doi:10.1097/QAI.0000000000003122
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.
Avery, E. F., Kleynhans, J. N., Ledergerber, B., Schoepf, I. C., Thorball, C. W., Kootstra, N. A., . . . Swiss HIV Cohort Study. (2023). Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(11), 1969-1979. doi:10.1093/cid/ciad033
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort Study.
Schoepf, I. C., Thorball, C. W., Kovari, H., Ledergerber, B., Buechel, R. R., Calmy, A., . . . Swiss HIV Cohort Study. (2023). Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort Study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(1), 48-56. doi:10.1093/cid/ciac758
Real-World Trough Concentrations and Effectiveness of Long-Acting Cabotegravir and Rilpivirine: A Multicenter Prospective Observational Study in Switzerland
What is the significance of the pharmacokinetic profile and potential drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
Bettonte, S., Berton, M., & Marzolini, C. (2023). What is the significance of the pharmacokinetic profile and potential drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine?. Expert Opinion on Drug Metabolism and Toxicology, 19(5), 243-247. doi:10.1080/17425255.2023.2223961
2022
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. CLINICAL PHARMACOLOGY & THERAPEUTICS, 112(6), 1191-1200. doi:10.1002/cpt.2646
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study
Aebi-Popp, K., Kahlert, C. R., Crisinel, P. A., Decosterd, L., Saldanha, S. A., Hoesli, I., . . . Marzolini, C. (2022). Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. Journal of Antimicrobial Chemotherapy, 77(12), 3436-3442. doi:10.1093/jac/dkac337
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus
Jakeman, B., Scherrer, A. U., Darling, K. E. A., Damas, J., Bieler-Aeschlimann, M., Hasse, B., . . . Vargas, M. (2022). Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 9(9). doi:10.1093/ofid/ofac457
Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics—Why Time Is Essential for Meaningful Collaborations
Franchini, F., Kusejko, K., Marzolini, C., Tellenbach, C., Rossi, S., Stampf, S., . . . Leichtle, A. B. (2022). Collaborative Challenges of Multi-Cohort Projects in Pharmacogenetics—Why Time Is Essential for Meaningful Collaborations. Jmir Formative Research, 6(9). doi:10.2196/36759
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021
Ryom, L., De Miguel, R., Cotter, A. G., Podlekareva, D., Beguelin, C., Waalewijn, H., . . . Behrens, G. M. N. (2022). Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Medicine, 23(8), 849-858. doi:10.1111/hiv.13268
Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models
Berton, M., Bettonte, S., Stader, F., Battegay, M., & Marzolini, C. (2022). Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models. Clinical Pharmacokinetics, 61(9), 1251-1270. doi:10.1007/s40262-022-01132-3
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
Girardin, F., Manuel, O., Marzolini, C., & Buclin, T. (2022). Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. Clinical Microbiology and Infection, 28(8), 1044-1046. doi:10.1016/j.cmi.2022.03.030
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille, P., Alves Saldanha, S., Schaller, F., Munting, A., Cavassini, M., Braun, D., . . . On Behalf Of The Swiss Hiv Cohort Study. (2022). Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.. Pharmaceutics, 14(8), 1588. doi:10.3390/pharmaceutics14081588
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
Otten, L. S., Piet, B., van den Heuvel, M. M., Marzolini, C., van Geel, R. M. J. M., Gulikers, J. L., . . . Heine, R. T. (2022). Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. European Respiratory Review, 31(164). doi:10.1183/16000617.0004-2022
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020)
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2022). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2050. doi:10.1093/jac/dkac111
Sex-related pharmacokinetic differences with aging
Stader, F., & Marzolini, C. (2022). Sex-related pharmacokinetic differences with aging. European Geriatric Medicine, 13(3), 559-565. doi:10.1007/s41999-021-00587-0
Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV
Zino, L., Kingma, J. S., Marzolini, C., Richel, O., Burger, D. M., & Colbers, A. (2022). Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV. Clinical Pharmacokinetics, 61(5), 619-635. doi:10.1007/s40262-022-01120-7
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. ANNALS OF INTERNAL MEDICINE, 175(5), 744-+. doi:10.7326/M22-0281
Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years
Schoepf, I. C., Thorball, C. W., Ledergerber, B., Kootstra, N. A., Reiss, P., Raffenberg, M., . . . Tarr, P. E. (2022). Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. Journal of Infectious Diseases, 225(9), 1581-1591. doi:10.1093/infdis/jiab603
Magnitude of Drug-Drug Interactions in Special Populations.
Bettonte, S., Berton, M., & Marzolini, C. (2022). Magnitude of Drug-Drug Interactions in Special Populations.. Pharmaceutics, 14(4), 789. doi:10.3390/pharmaceutics14040789
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV
Jacobs, T. G., Marzolini, C., Back, D. J., & Burger, D. M. (2022). Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(3), 568-573. doi:10.1093/jac/dkab412
Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection
Marzolini, C., Gibbons, S., van Oosterhout, J. J., & Khoo, S. (2022). Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. CLINICAL PHARMACOKINETICS, 61(3), 339-346. doi:10.1007/s40262-021-01098-8
Fluvoxamine for the treatment of COVID-19
Marzolini, C., Marra, F., Boyle, A., Khoo, S., & Back, D. J. (2022). Fluvoxamine for the treatment of COVID-19. LANCET GLOBAL HEALTH, 10(3), E331. doi:10.1016/S2214-109X(21)00592-1
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients
Stader, F., Battegay, M., Sendi, P., & Marzolini, C. (2022). Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. Clinical Pharmacology and Therapeutics, 111(3), 579-584. doi:10.1002/cpt.2402
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: A prospective cohort study
Jakeman, B., Scherrer, A., Battegay, M., Gunthard, H. F., Hachfeld, A., Calmy, A., . . . Marzolini, C. (2022). Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: A prospective cohort study. Journal of Antimicrobial Chemotherapy, 77(2), 492-499. doi:10.1093/jac/dkab386
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)
Scherrer, A. U., Traytel, A., Braun, D. L., Calmy, A., Battegay, M., Cavassini, M., . . . Günthard, H. F. (2022). Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 51(1), 33-34. doi:10.1093/ije/dyab141
Collaborative challenges of multi-cohort project in pharmacogenetics: why time is essential for meaningful collaborations (Preprint)
2021
Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient—a case report and review of the literature
Hollinger, A., Cueni, N., Marzolini, C., Dickenmann, M., Landmann, E., Battegay, M., . . . Leuppi-Taegtmeyer, A. (2021). Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient—a case report and review of the literature. AIDS Research and Therapy, 18(1). doi:10.1186/s12981-021-00382-8
Coronary artery disease-associated and longevity-associated polygenic risk scores for prediction of coronary artery disease events in persons living with human immunodeficiency virus: The swiss hiv cohort study
Schoepf, I. C., Thorball, C. W., Ledergerber, B., Engel, T., Raffenberg, M., Kootstra, N. A., . . . Tarr, P. E. (2021). Coronary artery disease-associated and longevity-associated polygenic risk scores for prediction of coronary artery disease events in persons living with human immunodeficiency virus: The swiss hiv cohort study. Clinical Infectious Diseases, 73(9), 1597-1604. doi:10.1093/cid/ciab521
Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
Stader, F., Battegay, M., & Marzolini, C. (2021). Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir. Clinical Pharmacology and Therapeutics, 110(5), 1231-1239. doi:10.1002/cpt.2221
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living with Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study
Roth, J. A., Radevski, G., Marzolini, C., Rauch, A., Günthard, H. F., Kouyos, R. D., . . . Battegay, M. (2021). Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living with Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. Journal of Infectious Diseases, 224(7), 1198-1208. doi:10.1093/infdis/jiaa236
Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug–drug interactions?
Allavena, C., & Marzolini, C. (2021). Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug–drug interactions?. Lancet Healthy Longevity, 2(10), e606-e607. doi:10.1016/S2666-7568(21)00227-0
Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: A prospective questionnaire-based study
Kuemmerle, A., Sikalengo, G., Vanobberghen, F., Ndege, R. C., Foe, G., Schlaeppi, C., . . . Herieth, W. (2021). Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: A prospective questionnaire-based study. Journal of Antimicrobial Chemotherapy, 76(10), 2681-2689. doi:10.1093/jac/dkab254
Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Hodge, D., Back, D. J., Gibbons, S., Khoo, S. H., & Marzolini, C. (2021). Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. CLINICAL PHARMACOKINETICS, 60(7), 835-853. doi:10.1007/s40262-021-01005-1
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
Courlet, P., Guidi, M., Alves Saldanha, S., Cavassini, M., Stoeckle, M., Buclin, T., . . . Csajka, C. (2021). Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 77(7), 979-987. doi:10.1007/s00228-020-03060-2
Global genomic analysis of SARS-CoV-2 RNA dependent RNA polymerase evolution and antiviral drug resistance
Mari, A., Roloff, T., Stange, M., Søgaard, K. K., Asllanaj, E., Tauriello, G., . . . Egli, A. (2021). Global genomic analysis of SARS-CoV-2 RNA dependent RNA polymerase evolution and antiviral drug resistance. Microorganisms, 9(5). doi:10.3390/microorganisms9051094
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV
Stader, F., Courlet, P., Decosterd, L. A., Battegay, M., & Marzolini, C. (2021). Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. Clinical Pharmacology and Therapeutics, 109(4), 1025-1029. doi:10.1002/cpt.2178
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity
Livio, F., Deutschmann, E., Moffa, G., Rrustemi, F., Stader, F., Elzi, L., . . . Yerly, S. (2021). Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. Journal of Antimicrobial Chemotherapy, 76(3), 758-764. doi:10.1093/jac/dkaa505
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
Courlet, P., Guidi, M., Alves Saldanha, S., Stader, F., Traytel, A., Cavassini, M., . . . Csajka, C. (2021). Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics, 60(3), 379-390. doi:10.1007/s40262-020-00946-3
Prescribing in COVID-19 patients: Should we take into account inflammation?
Marzolini, C., Battegay, M., Sendi, P., & Back, D. J. (2021). Prescribing in COVID-19 patients: Should we take into account inflammation?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(3), 719-721. doi:10.1111/bcp.14524
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
Marra, F., Smolders, E. J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A. J., . . . Back, D. (2021). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. DRUGS IN R&D, 21(1), 9-27. doi:10.1007/s40268-020-00333-0
Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly
Stader, F., Courlet, P., Kinvig, H., Penny, M. A., Decosterd, L. A., Battegay, M., . . . Marzolini, C. (2021). Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. CLINICAL PHARMACOLOGY & THERAPEUTICS, 109(2), 471-484. doi:10.1002/cpt.2017
Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation
Stader, F., Courlet, P., Kinvig, H., Battegay, M., Decosterd, L. A., Penny, M. A., . . . Marzolini, C. (2021). Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(2), 458-470. doi:10.1111/bcp.14402
Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19
Marzolini, C., Stader, F., Leuppi-Taegtmeyer, A., Stoeckle, M., Battegay, M., & Sendi, P. (2021). Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19. Drug Safety, 44(2), 255-257. doi:10.1007/s40264-020-01025-z
Global surveillance of potential antiviral drug resistance in SARS-CoV-2: proof of concept focussing on the RNA-dependent RNA polymerase
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions
Back, D., Marzolini, C., Hodge, D., Marra, F., Boyle, A., Gibbons, S., . . . Khoo, S. (2021). COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(1), 212-213. doi:10.1111/bcp.14358
Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
Istampoulouoglou, I., Zimmermanns, B., Grandinetti, T., Marzolini, C., Harings-Kaim, A., Koechlin-Lemke, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre. Global Cardiology Science and Practice, 2021(2). doi:10.21542/GCSP.2021.11
2020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(12), 3417-3424. doi:10.1093/jac/dkaa340
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
Ryom, L., Cotter, A., De Miguel, R., Béguelin, C., Podlekareva, D., Arribas, J. R., . . . Wensing, A. (2020). 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Medicine, 21(10), 617-624. doi:10.1111/hiv.12878
Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
Bukkems, V. E., Colbers, A., Marzolini, C., Molto, J., & Burger, D. M. (2020). Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?. Clinical Pharmacokinetics, 59(10), 1217-1236. doi:10.1007/s40262-020-00914-x
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Stader, F., Khoo, S., Stoeckle, M., Back, D., Hirsch, H. H., Battegay, M., & Marzolini, C. (2020). Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(10), 3084-3086. doi:10.1093/jac/dkaa253
Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors
Deutschmann, E., Bucher, H. C., Jaeckel, S., Gibbons, S., McAllister, K., Scherrer, A., . . . Study, S. H. I. V. C. (2020). Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors. Clinical Infectious Diseases, 20, 40. doi:10.1093/cid/ciaa918
Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations
Marzolini, C., Stader, F., Stoeckle, M., Franzeck, F., Egli, A., Bassetti, S., . . . Sendi, P. (2020). Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. Antimicrobial Agents and Chemotherapy, 64(9). doi:10.1128/AAC.01177-20
Potentially inappropriate medications in older adults living with HIV
Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., Bellon, J. M., Perez-Latorre, L., Lopez, J. C., . . . Berenguer, J. (2020). Potentially inappropriate medications in older adults living with HIV. HIV MEDICINE, 21(8), 541-546. doi:10.1111/hiv.12883
Changes in renal function after switching from TDF to TAF in HIV-infected individuals: A prospective cohort study
Surial, B., Ledergerber, B., Calmy, A., Cavassini, M., Günthard, H. F., Kovari, H., . . . Yerly, S. (2020). Changes in renal function after switching from TDF to TAF in HIV-infected individuals: A prospective cohort study. Journal of Infectious Diseases, 222(4), 637-645. doi:10.1093/infdis/jiaa125
Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
Courlet, P., Decosterd, L. A., Alves Saldanha, S., Cavassini, M., Stader, F., Stoeckle, M., . . . Guidi, M. (2020). Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics, 59(8), 1037-1048. doi:10.1007/s40262-020-00876-0
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study
Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., McAllister, K., Bellon, J. M., Gibbons, S., . . . Berenguer, J. (2020). Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. In CLINICAL INFECTIOUS DISEASES Vol. 71 (pp. 353-362). doi:10.1093/cid/ciz811
Real-life management of drug-drug interactions between antiretrovirals and statins
Courlet, P., Livio, F., Alves Saldanha, S., Scherrer, A., Battegay, M., Cavassini, M., . . . Marzolini, C. (2020). Real-life management of drug-drug interactions between antiretrovirals and statins. Journal of Antimicrobial Chemotherapy, 75(7), 1972-1980. doi:10.1093/jac/dkaa099
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
Courlet, P., Alves Saldanha, S., Cavassini, M., Marzolini, C., Choong, E., Csajka, C., . . . Decosterd, L. A. (2020). Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. Journal of Mass Spectrometry, 55(6). doi:10.1002/jms.4506
Aging does not impact drug-Drug interaction magnitudes with antiretrovirals
Stader, F., Decosterd, L., Stoeckle, M., Cavassini, M., Battegay, M., Saldanha, S. A., . . . Courlet, P. (2020). Aging does not impact drug-Drug interaction magnitudes with antiretrovirals. AIDS, 34(6), 949-952. doi:10.1097/QAD.0000000000002489
Cobicistat: A case of mislabelled drug-drug interaction risk?
Burger, D. M., Calmy, A., & Marzolini, C. (2020). Cobicistat: A case of mislabelled drug-drug interaction risk?. British Journal of Clinical Pharmacology, 86(5), 834-836. doi:10.1111/bcp.14262
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need
Guaraldi, G., Maurice, J. B., Marzolini, C., Monteith, K., Milic, J., Tsochatzis, E., . . . Sebastiani, G. (2020). New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology, 71(5), 1831-1844. doi:10.1002/hep.31177
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly
Stader, F., Kinvig, H., Penny, M. A., Battegay, M., Siccardi, M., & Marzolini, C. (2020). Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. CLINICAL PHARMACOKINETICS, 59(3), 383-401. doi:10.1007/s40262-019-00822-9
The challenge of HIV treatment in an era of polypharmacy
Back, D., & Marzolini, C. (2020). The challenge of HIV treatment in an era of polypharmacy. Journal of the International AIDS Society, 23(2). doi:10.1002/jia2.25449
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV
Courlet, P., Stader, F., Guidi, M., Alves Saldanha, S., Stoeckle, M., Cavassini, M., . . . Marzolini, C. (2020). Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS, 34(1), 103-108. doi:10.1097/QAD.0000000000002372
Prevalence and management of drug–drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study
Schlaeppi, C., Vanobberghen, F., Sikalengo, G., Glass, T. R., Ndege, R. C., Foe, G., . . . Wilson, H. I. (2020). Prevalence and management of drug–drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. HIV Medicine, 21(1), 53-63. doi:10.1111/hiv.12801
2019
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine
Boyle, A., Hodge, D., Marzolini, C., & Khoo, S. (2019). Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. CLINICAL PHARMACOKINETICS, 58(12), 1553-1565. doi:10.1007/s40262-019-00806-9
Polypharmacy, drug–drug interactions, and inappropriate drugs: New challenges in the aging population with HIV
Courlet, P., Livio, F., Guidi, M., Cavassini, M., Battegay, M., Stoeckle, M., . . . Yerly, S. (2019). Polypharmacy, drug–drug interactions, and inappropriate drugs: New challenges in the aging population with HIV. Open Forum Infectious Diseases, 6(12). doi:10.1093/ofid/ofz531
Current challenges and solutions in research and clinical care of older persons living with HIV: Findings presented at the 9th international workshop on HIV and aging
Sundermann, E. E., Erlandson, K. M., Pope, C. N., Rubtsova, A., Montoya, J., Moore, A. A., . . . Moore, D. J. (2019). Current challenges and solutions in research and clinical care of older persons living with HIV: Findings presented at the 9th international workshop on HIV and aging. In AIDS Research and Human Retroviruses Vol. 35 (pp. 985-998). doi:10.1089/aid.2019.0100
Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics
Brockhaus, L., Goldblum, D., Eggenschwiler, L., Zimmerli, S., & Marzolini, C. (2019). Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection, 25(11), 1364-1369. doi:10.1016/j.cmi.2019.01.017
Population pharmacokinetics of dolutegravir: Influence of drug-drug interactions in a real-life setting
Barcelo, C., Aouri, M., Courlet, P., Guidi, M., Braun, D. L., Günthard, H. F., . . . Yerly, S. (2019). Population pharmacokinetics of dolutegravir: Influence of drug-drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 74(9), 2690-2697. doi:10.1093/jac/dkz217
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV
Courlet, P., Spaggiari, D., Desfontaine, V., Cavassini, M., Alves Saldanha, S., Buclin, T., . . . Decosterd, L. A. (2019). UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 1125. doi:10.1016/j.jchromb.2019.121733
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence
Courlet, P., Decosterd, L. A., Brown, J. A., Saldanha, S. A., Marzolini, C., Cavassini, M., . . . Calmy, A. (2019). Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. Journal of Antimicrobial Chemotherapy, 74(8), 2468-2470. doi:10.1093/jac/dkz181
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017
Ruffieux, Y., Lemsalu, L., Aebi-Popp, K., Calmy, A., Cavassini, M., Fux, C. A., . . . Yerly, S. T. B. D. (2019). Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017. Journal of the International AIDS Society, 22(8). doi:10.1002/jia2.25339
Prescribing issues in elderly individuals living with HIV
Marzolini, C., & Livio, F. (2019). Prescribing issues in elderly individuals living with HIV. Expert Review of Clinical Pharmacology, 12(7), 643-659. doi:10.1080/17512433.2019.1627200
Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
Stader, F., Siccardi, M., Battegay, M., Kinvig, H., Penny, M. A., & Marzolini, C. (2019). Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. CLINICAL PHARMACOKINETICS, 58(4), 483-501. doi:10.1007/s40262-018-0709-7
Pharmacokinetics, Placental and Breastmilk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.
Hodel, E. M., Marzolini, C., Waitt, C., & Rakhmanina, N. (2019). Pharmacokinetics, Placental and Breastmilk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.. Current Pharmaceutical Design. doi:10.2174/1381612825666190320162507
A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®.
Stader, F., Penny, M. A., Siccardi, M., & Marzolini, C. (2019). A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®.. CPT: pharmacometrics & systems pharmacology. doi:10.1002/psp4.12399
Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website
Gibbons, S., Marzolini, C., Hodge, D., McAllister, K., Chiong, J., Back, D., & Khoo, S. (2019). Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website. In HIV MEDICINE Vol. 20 (pp. 44-45).
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment
Courlet, P., Guidi, M., Glatard, A., Alves Saldanha, S., Cavassini, M., Buclin, T., . . . Csajka, C. (2019). Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment. British Journal of Clinical Pharmacology, 85(9), 2022-2032. doi:10.1111/bcp.13994
Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain
Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., Bellon-Cano, J. M., Perez-Latorre, L., Lopez, J. C., . . . Berenguer, J. (2019). Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain. In HIV MEDICINE Vol. 20 (pp. 132). Retrieved from https://www.webofscience.com/
Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
Livio, F., & Marzolini, C. (2019). Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs. Therapeutic Advances in Drug Safety, 10. doi:10.1177/2042098619880122
2018
HIV and Aging - Perhaps Not as Dramatic as We Feared?
Engel, T., Raffenberg, M., Marzolini, C., Cavassini, M., Kovari, H., Hasse, B., & Tarr, P. E. (2018). HIV and Aging - Perhaps Not as Dramatic as We Feared?. Gerontology, 64(5), 446-456. doi:10.1159/000489172
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0
Ryom, L., Boesecke, C., Bracchi, M., Ambrosioni, J., Pozniak, A., Arribas, J., . . . Volny-Anne, A. (2018). Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV Medicine, 19(5), 309-315. doi:10.1111/hiv.12600
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods
Baettig, V., Courlet, P., Delko, T., Battegay, M., & Marzolini, C. (2018). Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods. AIDS, 32(13), 1903-1905. doi:10.1097/QAD.0000000000001913
2017
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report
Marzolini, C., Decosterd, L., Winterfeld, U., Tissot, F., Francini, K., Buclin, T., & Livio, F. (2017). Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. British Journal of Clinical Pharmacology, 83(12), 2835-2838. doi:10.1111/bcp.13310
Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems
Erb, S., Letang, E., Glass, T. R., Natamatungiro, A., Mnzava, D., Mapesi, H., . . . Vanobberghen, F. (2017). Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. HIV Medicine, 18(9), 623-634. doi:10.1111/hiv.12499
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir
Bartels, H., Decosterd, L., Battegay, M., & Marzolini, C. (2017). Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. Journal of Antimicrobial Chemotherapy, 72(9), 2574-2577. doi:10.1093/jac/dkx165
Adverse events of raltegravir and dolutegravir
Elzi, L., Erb, S., Furrer, H., Cavassini, M., Calmy, A., Vernazza, P., . . . Yerly, S. (2017). Adverse events of raltegravir and dolutegravir. AIDS, 31(13), 1853-1858. doi:10.1097/QAD.0000000000001590
Dolutegravir plasma levels after gastric bypass surgery
Piso, R. J., Battegay, M., & Marzolini, C. (2017). Dolutegravir plasma levels after gastric bypass surgery. AIDS, 31(7), 1052-1054. doi:10.1097/QAD.0000000000001438
Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., & Siccardi, M. (2017). Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. CLINICAL PHARMACOKINETICS, 56(4), 409-420. doi:10.1007/s40262-016-0447-7
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
Seden, K., Gibbons, S., Marzolini, C., Schapiro, J. M., Burger, D. M., Back, D. J., & Khoo, S. H. (2017). Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173509
2016
Privacy-preserving genomic testing in the clinic: A model using HIV treatment
Mclaren, P. J., Raisaro, J. L., Aouri, M., Rotger, M., Ayday, E., Bartha, I., . . . Telenti, A. (2016). Privacy-preserving genomic testing in the clinic: A model using HIV treatment. Genetics in Medicine, 18(8), 814-822. doi:10.1038/gim.2015.167
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
Marzolini, C., Gibbons, S., Khoo, S., & Back, D. (2016). Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1755-1758. doi:10.1093/jac/dkw032
Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons
Ryom, L., Boesecke, C., Gisler, V., Manzardo, C., Rockstroh, J. K., Puoti, M., . . . Youle, M. (2016). Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Medicine, 17(2), 83-88. doi:10.1111/hiv.12322
2015
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies
Moss, D. M., Marzolini, C., Rajoli, R. K. R., & Siccardit, M. (2015). Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 11(8), 1203-1217. doi:10.1517/17425255.2015.1037278
Etravirine: a good option for concomitant use with chemotherapy for Hodgkin’s lymphoma
Kurz, M., Stoeckle, M., Krasniqi, F., Battegay, M., & Marzolini, C. (2015). Etravirine: a good option for concomitant use with chemotherapy for Hodgkin’s lymphoma. International Journal of STD and AIDS, 26(3), 212-214. doi:10.1177/0956462414533517
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
Marzolini, C., Sabin, C., Raffi, F., Siccardi, M., Mussini, C., Launay, O., . . . Battegay, M. (2015). Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS, 29(2), 193-200. doi:10.1097/QAD.0000000000000530
2014
Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study
Hasse, B., Iff, M., Ledergerber, B., Calmy, A., Schmid, P., Hauser, C., . . . Yerly, S. (2014). Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study. Open Forum Infectious Diseases, 1(2). doi:10.1093/ofid/ofu040
Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus
Lakatos, B., Stoeckle, M., Elzi, L., Battegay, M., & Marzolini, C. (2014). Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Medical Weekly, 144. doi:10.4414/smw.2014.13906
2013
Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 52(7), 613-614. doi:10.1007/s40262-013-0066-5
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7
The brain entry of HIV-1 protease inhibitors is facilitated when used in combination
Marzolini, C., Mueller, R., Li-Blatter, X., Battegay, M., & Seelig, A. (2013). The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. Molecular Pharmaceutics, 10(6), 2340-2349. doi:10.1021/mp300712a
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals
Lubomirov, R., Arab-Alameddine, M., Rotger, M., Fayet-Mello, A., Martinez, R., Guidi, M., . . . Talenti, A. (2013). Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 23(1), 9-18. doi:10.1097/FPC.0b013e32835ade82
2012
Efavirenz in an obese HIV-infected patient - a report and an <i>in vitro</i>-<i>in vivo</i> extrapolation model indicate risk of underdosing
de Roche, M., Siccardi, M., Stoeckle, M., Livio, F., Back, D., Battegay, M., & Marzolini, C. (2012). Efavirenz in an obese HIV-infected patient - a report and an <i>in vitro</i>-<i>in vivo</i> extrapolation model indicate risk of underdosing. ANTIVIRAL THERAPY, 17(7), 1381-1384. doi:10.3851/IMP2107
Maternal antiretroviral prophylaxis and breastfeeding
Marzolini, C., & Gray, G. E. (2012). Maternal antiretroviral prophylaxis and breastfeeding. Antiviral Therapy, 17(8), 1503-1506. doi:10.3851/IMP2314
Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2012). Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 60. doi:10.7448/IAS.15.6.18339
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy
Glass, T. R., Rotger, M., Telenti, A., Decosterd, L., Csajka, C., Bucher, H. C., . . . Marzolini, C. (2012). Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. Plos One, 7(1). doi:10.1371/journal.pone.0029186
2011
Drug-drug interactions with HIV treatments
Mossdorf, E., Marzolini, C., Fasel, D., Mello Fayet, A., Blum, C., Donath, M., & Battegay, M. (2011). Drug-drug interactions with HIV treatments. Praxis, 100(19), 1193-1196. doi:10.1024/1661-8157/a000673
Ageing with HIV: Medication use and risk for potential drug-drug interactions
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Yerly, S. (2011). Ageing with HIV: Medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248
Ageing with HIV: medication use and risk for potential drug-drug interactions
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Yerly, S. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248
2010
ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformuiated with ritonavir
Lubomirov, R., Lulio, J. D., Fayet, A., Colombo, S., Martinez, R., Marzolini, C., . . . Telenti, A. (2010). ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformuiated with ritonavir. Pharmacogenetics and Genomics, 20(4), 217-230. doi:10.1097/FPC.0b013e328336eee4
Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Battegay, M. (2010). Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3), 413-423. doi:10.3851/imp1540
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008
Elzi, L., Marzolini, C., Furrer, H., Ledergerber, B., Cavassini, M., Hirschel, B., . . . Battegay, M. (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1), 57-65. doi:10.1001/archinternmed.2009.432
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study
Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Battegay, M. (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV cohort study. Antiviral Therapy, 15(3), 413-423. doi:10.3851/IMP1540
2009
Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus
Mertz, D., Battegay, M., Marzolini, C., & Mayr, M. (2009). Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus. American Journal of Kidney Diseases, 54(1), e1-e4. doi:10.1053/j.ajkd.2009.01.268
2008
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity
Krishnamurthy, P., Schwab, M., Takenaka, K., Nachagari, D., Morgan, J., Leslie, M., . . . Schuetz, J. D. (2008). Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Research, 68(13), 4983-4989. doi:10.1158/0008-5472.CAN-07-6790
2007
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression
Marzolini, C., Tirona, R. G., Gervasini, G., Poonkuzhali, B., Assem, M., Lee, W., . . . Kim, R. B. (2007). A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Molecular Endocrinology, 21(8), 1769-1780. doi:10.1210/me.2007-0025
2006
Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction
Colombo, S., Béguin, A., Marzolini, C., Telenti, A., Biollaz, J., & Decosterd, L. A. (2006). Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 832(1), 138-143. doi:10.1016/j.jchromb.2005.11.040
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study
Ribaudo, H. J., Haas, D. W., Tierney, C., Kim, R. B., Wilkinson, G. R., Gulick, R. M., . . . Acosta, E. P. (2006). Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study. Clinical Infectious Diseases, 42(3), 401-407. doi:10.1086/499364
2005
Placental transfer of antiretroviral drugs
Marzolini, C., & Kim, R. B. (2005). Placental transfer of antiretroviral drugs. Clinical Pharmacology and Therapeutics, 78(2), 118-122. doi:10.1016/j.clpt.2005.05.002
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
Fellay, J., Marzolini, C., Decosterd, L., Golay, K. P., Baumann, P., Buclin, T., . . . Eap, C. B. (2005). Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. European Journal of Clinical Pharmacology, 60(12), 865-873. doi:10.1007/s00228-004-0855-8
Pharmacogenetics of drug transporters
Marzolini, C., Tirona, R. G., & Kim, R. B. (2005). Pharmacogenetics of drug transporters. In Pharmacogenomics Second Edition (pp. 109-155).
2004
Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., . . . Acosta, E. P. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS, 18(18), 2391-2400.
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction
Colombo, S., Guignard, N., Marzolini, C., Telenti, A., Biollaz, J., & Decosterd, L. A. (2004). Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 810(1), 25-34. doi:10.1016/j.jchromb.2004.07.008
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.
Colombo, S., Guignard, N., Marzolini, C., Telenti, A., Biollaz, J., & Decosterd, L. A. (2004). Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 810(1), 25-34. doi:10.1016/j.jchromb.2004.07.008
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
Csajka, C., Marzolini, C., Fattinger, K., Décosterd, L. A., Telenti, A., Biollaz, J., & Buclin, T. (2004). Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, 48(9), 3226-3232. doi:10.1128/AAC.48.9.3226-3232.2004
Pharmacogenomics of the OATP and OAT families
Marzolini, C., Tirona, R. G., & Kim, R. B. (2004). Pharmacogenomics of the OATP and OAT families. Pharmacogenomics, 5(3), 273-282. doi:10.1517/phgs.5.3.273.29831
MDR1 Genetic Polymorphism Does Not Modify either Cell Permissiveness to HIV-1 or Disease Progression before Treatment
Bleiber, G., May, M., Suarez, C., Martinez, R., Marzolini, C., Egger, M., & Telenti, A. (2004). MDR1 Genetic Polymorphism Does Not Modify either Cell Permissiveness to HIV-1 or Disease Progression before Treatment. Journal of Infectious Diseases, 189(4), 583-586. doi:10.1086/380134
Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance
Marzolini, C., Paus, E., Buclin, T., & Kim, R. B. (2004). Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clinical Pharmacology and Therapeutics, 75(1), 13-33. doi:10.1016/j.clpt.2003.09.012
2003
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
Csajka, C., Marzolini, C., Fattinger, K., Décosterd, L. A., Fellay, J., Telenti, A., . . . Buclin, T. (2003). Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 73(1), 20-30. doi:10.1067/mcp.2003.22
2002
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients [2]
Doser, N., Kübli, S., Telenti, A., Marzolini, C., Chave, J. P., Feihl, F., . . . Mooser, V. (2002). Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients [2]. AIDS, 16(14), 1982-1983. doi:10.1097/00002030-200209270-00024
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: Application for the assessment of their transplacental passage at delivery
Marzolini, C., Béguin, A., Telenti, A., Schreyer, A., Buclin, T., Biollaz, J., & Decosterd, L. A. (2002). Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: Application for the assessment of their transplacental passage at delivery. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 774(2), 127-140. doi:10.1016/S1570-0232(02)00169-1
Transplacental passage of protease inhibitors at delivery
Marzolini, C., Rudin, C., Decosterd, L. A., Telenti, A., Schreyer, A., Biollaz, J., . . . Wyler, C. A. (2002). Transplacental passage of protease inhibitors at delivery. AIDS, 16(6), 889-893. doi:10.1097/00002030-200204120-00008
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., . . . Telenti, A. (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. LANCET, 359(9300), 30-36. doi:10.1016/S0140-6736(02)07276-8
2001
Rote of therapeutic drug monitoring for antiretrovirals in HIV-1 patients care
Marzolini, C., Decosterd, L. A., Buclin, T., Telenti, A., & Biollaz, J. (2001). Rote of therapeutic drug monitoring for antiretrovirals in HIV-1 patients care. Medecine Et Hygiene, 59(2369), 2302-2305.
Impaired absorption of rifabutin by concomitant administration of didanosine [3]
Marzolini, C., Chave, J. P., Telenti, A., Brenas-Chinchon, L., & Biollaz, J. (2001). Impaired absorption of rifabutin by concomitant administration of didanosine [3]. AIDS, 15(16), 2203-2204. doi:10.1097/00002030-200111090-00022
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: High interpatient and low intrapatient variability
Marzolini, C., Buclin, T., Decosterd, L. A., Biollaz, J., & Telenti, A. (2001). Nelfinavir plasma levels under twice-daily and three-times-daily regimens: High interpatient and low intrapatient variability. Therapeutic Drug Monitoring, 23(4), 394-398. doi:10.1097/00007691-200108000-00012
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
Marzolini, C., Telenti, A., Decosterd, L., Biollaz., & Buclin, T. J. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15(9), 1193-1194. doi:10.1097/00002030-200106150-00023
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15(1), 71-75. doi:10.1097/00002030-200101050-00011
2000
Efavirenz decreases methadone blood concentrations
Marzolini, C., Troillet, N., Telenti, A., Baumann, P., Decosterd, L. A., & Eap, C. B. (2000). Efavirenz decreases methadone blood concentrations. AIDS, 14(9), 1291-1292. doi:10.1097/00002030-200006160-00036
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction
Marzolini, C., Telenti, A., Buclin, T., Biollaz, J., & Decosterd, L. A. (2000). Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. Journal of Chromatography B Biomedical Sciences and Applications, 740(1), 43-58. doi:10.1016/S0378-4347(99)00573-3
1999
Erratum: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration (Cancer Chemotherapy and Pharmacology (1998) 42 (433-440))
Marzolini, C., Decosterd, L. A., Gander, F. S. M., Leyvraz, S., Bauer, J., Buclin, T., . . . Lejeune, F. (1999). Erratum: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration (Cancer Chemotherapy and Pharmacology (1998) 42 (433-440)). Cancer Chemotherapy and Pharmacology, 43(5), 439-440. doi:10.1007/s002800050920
Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours
Gander, M., Leyvraz, S., Decosterd, L., Bonfanti, M., Marzolini, C., Shen, F., . . . D'Incalci, M. (1999). Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Annals of Oncology, 10(7), 831-838. doi:10.1023/A:1008304032421
1998
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration
Marzolini, C., Decosterd, L. A., Shen, F., Gander, M., Leyvraz, S., Bauer, J., . . . Lejeune, F. (1998). Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemotherapy and Pharmacology, 42(6), 433-440. doi:10.1007/s002800050842